HIV treatment as prevention and HPTN 052.
HIV treatment as prevention and HPTN 052.
复制标题
DOI：
10.1097/coh.0b013e32834f5cf2
复制
发表时间：
2012-03
影响因子：
4.1
通讯作者：
Gamble TR
中科院分区：
文献类型：
--
作者：
Cohen MS;McCauley M;Gamble TR
本文综述了一项大型临床试验HIV预防试验网络（HPTN）052的开发和实施，该试验的初步结果最近已提交并发表。一项随机临床试验表明，抗逆转录病毒疗法可将艾滋病毒血清不一致夫妇的艾滋病毒性传播减少96%以上。筹备和进行这一审判的后勤挑战相当大。HPTN 052需要多年的准备，国家卫生研究院和六家制药公司之间的大量合作，以及对大量伦理问题的仔细考虑。HPTN 052揭示了使用抗逆转录病毒疗法预防艾滋病毒传播的益处，并作为概念的证明。事实证明，这些结果对于制定新的全球艾滋病毒预防工作至关重要。
This review summarizes the development and implementation of a large clinical trial, HIV Prevention Trials Network (HPTN) 052, whose initial results were recently presented and published. A randomized, clinical trial demonstrated that antiretroviral therapy reduces the sexual transmission of HIV in HIV-serodiscordant couples by more than 96%. The logistical challenges in preparing for and conducting such a trial were considerable. HPTN 052 required many years of preparation, considerable collaboration between National Institute of Health and six pharmaceutical companies, and careful ongoing consideration of a large number of ethical issues. HPTN 052 revealed the magnitude of benefit when using antiretroviral therapy to prevent the transmission of HIV, and served as proof of a concept. The results have proven central to the development of new global HIV-prevention efforts.